Oxaliplatin
Oxaliplatin is a platinum-based cross-linking agent that exhibits anticancer chemotherapeutic activity. Oxaliplatin inhibits DNA replication and transcription and is clinically used to treat colon cancer. In hepatocellular carcinoma cells, oxaliplatin induces S phase cell cycle arrest, downregulates expression of CDK4 and cyclin D1, upregulates expression of p21 and p53, and inhibits cellular proliferation.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18951529
| Cas No. |
61825-94-3 |
|---|---|
| Purity |
≥98% |
| Formula |
C8H14N2O4Pt |
| Formula Wt. |
397.29 |
| Chemical Name |
(SP-4-2)-[(1R,2R)-1.2-Cyclohexanediamine-κN,κN]- [ethanedioato(2-)-κO1,κO2]platinum |
| Synonym |
Oxalatoplatin; Oxalatoplatinum |
| Melting Point |
260°C |
| Solubility |
Soluble in water (10 mM, 4 mg/mL), DMSO (50 mM or 20 mg /mL). |
| Appearance |
White Crystalline powder |
Chen X, Wu Y, Dong H, et al. Platinum-based agents for individualized cancer treatment. Curr Mol Med. 2013 Dec;13(10):1603-12. PMID: 24206132.
Gao J, Wang R, Yang Q, et al. Effect of Oxaliplatin on cell cycle of hepatocellular carcinoma cell line HepG2. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013 Jul;42(4):437-42. PMID: 24022933.
Graham J, Mushin M, Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discov. 2004 Jan;3(1):11-2. PMID: 14756144.
